Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Eli Lilly and Company and Regeneron have applied to the US Food and Drug Administration for emergency use authorizations (EUAs) for their COVID-19 monoclonal antibodies, which block the entry of SARS-CoV-2 into human cells. Both firms have released early data from clinical trials showing that their antibodies reduce viral load and have some effect on symptoms. Regeneron, which provided its treatment to President Donald J. Trump, has said it will initially make the drug available for free; Lilly has said it would like to do the same.
This article has been sent to the following recipient: